Total Funding
95
90
Total FundingGrant raised
Growth Score
18 pts
Heat Score
29 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
6584
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
- Dr. Gili Hart: CEOPast Role: Mitoconix Bio, Chief Executive Officer
- Prof. Batsheva Kerem: CSO and Scientific Founder
About the Company
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR
transcripts according to the specific mutation carried.
